PLASMA LEPTIN LEVELS IN METABOLIC SYNDROME PATIENTS WITH ISCHEMIC HEART DISEASE
https://doi.org/10.15829/1728-8800-2016-3-43-48
Abstract
Aim. To assess leptin level in blood serum of patients with metabolic syndrome (MS), including comorbidity with ischemic heart disease (IHD), to reveal possible predictive value of this marker for IHD development in MS.
Material and methods. Totally, 43 MS patients studied, of those 36 with IHD, and 33 non-MS, among those had been diagnosed with IHD 18. Mean age of the MS patients at baseline was 62,7±10,3 y.o. Controls (non-MS) were 60±14,7 y.o. Leptin level in serum was measured via immune-enzyme assay “Platinum ELISA”.
Results. Mean level of leptin in MS groups was significantly higher — 41,89±33,28 ng/mL comparing to non-MS — 17,64±16,87 ng/mL (р<0,001). Women had higher leptin level — 38,65±29,23 ng/mL, comparing to men — 19,54±27,23 ng/mL (р=0,006). A direct correlation of leptin and IHD was found (r=0,258, p=0,024).
Conclusion. Leptin level in MS patients is higher than non-MS. Leptin plasma level in MS and IHD is higher than MS non-IHD. Further study and understanding of possible leptin mechanisms of action might be applied in improvement of effectiveness of earlier IHD diagnostics in MS.
About the Authors
O. M. Drapkina
National Research Center for Preventive Medicine, Moscow
R. N. Shepel
National Research Center for Preventive Medicine, Moscow
Russian Federation
Russian Federation
T. A. Deeva
I.M. Sechenov First Moscow State Medical University, Moscow
References
1. . Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens 2004; 13 (2): 215-23.
2. WHO. Obesity: Preventing and Managing the Global Epidemic. World Health Organisation: 2000. (www.who.int), Fact sheet N°311, 2015. 185
3. Recommendations Project Experts of the Russian Society of Cardiology for the diagnosis and treatment of metabolic syndrome, the third revision of 2013. www. scardio.ru›content/Guidelines/projectrecomMS.doc (10 March 2016)
4. Dedov II, Mel’nichenko GA, Butrova SA. Adipose tissue as an endocrine organ. Obesity and Metabolism 2006; 1 (6): 6-13. Russian (Дедов И.И., Мельниченко Г.А., Бутрова С.А. Жировая ткань как эндокринный орган. Ожирение и метаболизм 2006; 1(6): 6-13).
5. Piemonti L, Calori G, Mercgulation A, et al. Fasting plasma leptin, tumor necrosis factor–alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucosetolerant and glucose–intolerant women: impact on cardiovascular mortality. Diabetes Care 2003; 26: 2883-9.
6. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West Of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001; 104: 3052-6.
7. Wallerstedt SM, Eriksson AL, Niklason A, et al. Serum leptin and myocardial infarction in hypertension. Blood Press 2004; 13: 243-6.
8. Alberti KGMM, Zimmet PZ, Shaw JE. The Metabolic Syndrome — а new worldwide definition from the International Diabetes Federation Consensus. Lancet 2005; 366: 1059-62.
9. Vasjuk JuA, Sadulaeva IA, Jushhuk EN. Metabolic syndrome: new aspects of an old problem. Arterial Hypertension 2007; 13 (2): 34-6. Russian (Васюк Ю.А., Садулаева И.А., Ющук Е.Н. и др. Метаболический синдром: новые аспекты старой проблемы. Артериальная гипертензия 2007; 13(2): 34-6).
10. Hutley L, Prins J. Fat as an endocrine organ: relationship to the metabolic syndrome. Amer J Med Sciences 2005; 330(6): 280-9.
11. Kwang KK, Sang Min Park, Michael J. Quon. Leptin and Cardiovascular Disease. AHA 2008; 117: 3238-49.
12. Drapkina OM, Deeva TA, Popova IR. Nonalcoholic fatty liver disease as an obligatory sign of obesity. Russian Medical News 2012; 17(4): 4-10. Russian (Драпкина О. М., Деева Т. А., Попова И. Р. Неалкогольная жировая болезнь печени как облигатный признак ожирения. Российские Медицинские Вести 2012; 17(4): 4-10).
13. Wolk R, Berger P, Lennon RJ, et al. Plasma leptin and prognosis in patients with established coronary atherosclerosis. JACC 2004; 44(9):1819-24.
14. Abe Y, Ono K, Kawamura T, et al. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol 2007; 292 (5):2387-96.
15. Xu FP, Chen MS, Wang YZ, et al. Leptin induces hypertrophy via endothelin–1–reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 2004; 110: 1269-75.
16. Lieb W, Sullivan LM, Harris TB, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals. Diabetes Care 2009; 32 (4): 612-6.
17. Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens 2004; 13(2): 215-23.
Supplementary files
|
1. Титульный лист | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(32KB)
|
Indexing metadata ▾ | |
|
|
2. Сопроводительный лист | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(59KB)
|
Indexing metadata ▾ | |
|
3. Таблица 1 | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(12KB)
|
Indexing metadata ▾ | |
|
4. Рисунок 1-4 | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(98KB)
|
Indexing metadata ▾ | |
Review
For citations:
Drapkina O.M., Shepel R.N., Deeva T.A. PLASMA LEPTIN LEVELS IN METABOLIC SYNDROME PATIENTS WITH ISCHEMIC HEART DISEASE. Cardiovascular Therapy and Prevention. 2016;15(3):43-48. (In Russ.) https://doi.org/10.15829/1728-8800-2016-3-43-48
Views:
963
Email this article 
